Repros Therapeutics

Repros Therapeutics — Investor Day (October 2014)

119 slides from Repros Therapeutics's investor day presentation, Oct 31, 2014

  1. Slide 1: Androxal Analyst Day October 31, 2014

    Slide 1: Androxal Analyst Day October 31, 2014

    Androxal ® Analyst Day October 31, 2014 A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism

  2. Slide 2: Repros Disclaimer

    Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai

  3. Slide 3: Androxal Analyst Day Agenda

    Slide 3: Androxal Analyst Day Agenda

    Androxal Analyst Day Agenda • Quick overview of NDA status • KOL presentations – Key differences between TRT and restoration of the HPT axis in the treatment of the obese hypogonadal male – Review of 304 and 305 efficacy findings – Epidemiology of Hypogonadism • Key takeaways from the EMAS study – P

  4. Slide 4: Androxal NDA Status

    Slide 4: Androxal NDA Status

    Androxal NDA Status • FDA meeting to discuss NDA within the next two weeks • Anticipate NDA submission around year - end 2014 – Electronic submission ( Accenture Life Sciences contracted as consultant for content and service provider for assembly and cross linking) • Key NDA components – 23 preclini

  5. Slide 5: Androxal NDA Status (cont'd)

    Slide 5: Androxal NDA Status (cont'd)

    Androxal NDA Status • Key NDA components (cont’d) – Integrated summary of safety • Exceeds ICH requirements for exposure • > 1500 men exposed (any dose, any duration) • > 900 men for 6 months • > 200 men for 12 months • > 700 patient years of exposure – CMC components • DMF submitted to FDA by suppl

  6. Slide 6: The Changing Dynamic of the Treatment of Secondary Hypogonadism

    Slide 6: The Changing Dynamic of the Treatment of Secondary Hypogonadism

    Edward D. Kim, M.D. Professor of Surgery/Urology The Changing Dynamic of the Treatment of Secondary Hypogonadism

  7. Slide 7: Testosterone therapy suppresses pituitary function

    Slide 7: Testosterone therapy suppresses pituitary function

    • Testosterone therapy suppresses pituitary function and decreases testicular production of T • Exogenous T supplementation decreases sperm production. • Clomiphene, off - label, has become a standard therapy for men who desire to maintain future fertility. Rigourous studies are needed. Fertil Steri

  8. Slide 8: Age Distribution of T initiation

    Slide 8: Age Distribution of T initiation

    Age Distribution of T initiation Age ( yrs ) U.K. U.S.A. 18 - 39 15.6% 12.4% 40 - 64 61.0% 74.0% 65+ 23.6% 13.4% Layton JB et al. J Clin Endocrinol and Metab Jan 2014 . [ epub ahead ]:1 - 7 Most men starting TRT are <64 years of age. Many men are of reproductive age.

  9. Slide 9: EAU Guidelines on Male Hypogonadism

    Slide 9: EAU Guidelines on Male Hypogonadism

    EAU Guidelines on Male Hypogonadism European Association of Urology 2012 “We recommend measurement of serum LH and FSH levels to distinguish between primary (testicular) and secondary (pituitary - hypothalamic) hypogonadism .”

  10. Slide 10: Hypothalamic-pituitary-testicular axis

    Slide 10: Hypothalamic-pituitary-testicular axis

    Higher Centers Hypothalamus Anterior Pituitary Sertoli Cells Leydig Cell Germinal Epithelium GnRH FSH LH + + Inhibin - - - Testosterone

  11. Slide 11: Selective Estrogen Receptor Modulators: Clomiphene citrate

    Slide 11: Selective Estrogen Receptor Modulators: Clomiphene citrate

    Selective Estrogen Receptor Modulators: Clomiphene citrate • Competitively binds to estrogen receptors on the hypothalamus and pituitary • The pituitary sees less estrogen, and makes more LH, increasing T production by the testis • Off - label, 12.5 - 50 mg po daily or qod http://www.maledoc.com/blo

  12. Slide 12: Key Clinical Findings from Androxal Studies

    Slide 12: Key Clinical Findings from Androxal Studies

    Key Clinical Findings from Androxal Studies

  13. Slide 13: Age & BMI of Subjects in Repros Androxal Studies

    Slide 13: Age & BMI of Subjects in Repros Androxal Studies

    Age & BMI of Subjects in Repros Androxal Studies Study IND # of Subjects Mean Age Mean BMI ZN - 018 65,396 52 51.2 31.95 ZA - 003 65,396 194 52.6 32.4 ZA - 202 104,921 116 57.3 33.5 ZA - 203 65,396 108 50.7 32.0 ZA - 204 65,396 60 53.1 31.8 ZA - 300 65,396 499 48.6 33.0 ZA - 301 65,396 151 46.5 31.8

  14. Slide 14: Androxal Indication Statement

    Slide 14: Androxal Indication Statement

    Androxal Indication Statement “4.1 INDICATION FOR USE Androxal is indicated for the oral treatment of hypogonadotrophic hypogonadism (secondary hypogonadism) with preservation of testicular function (sperm concentration >15 million/mL and endogenous testosterone production) in men with BMI over 25.”

  15. Slide 15: ZA-304/305 study design

    Slide 15: ZA-304/305 study design

    ZA - 304/305 • Comparison of Androxal, Androgel 1.62% and Placebo • Double dummy, double blind parallel design with titration provisions within an arm – 40 per arm – Men < 60 years old and BMI > 25 – Confirmed morning T < 300 ng/dL – Average sperm counts at baseline > 15 million per mL • Primary end

  16. Slide 16: Androxal Preserves the HPT Axis

    Slide 16: Androxal Preserves the HPT Axis

    Study ZA - 305 Androxal Preserves the HPT Axis 0 1 2 3 4 5 6 7 8 9 0 100 200 300 400 500 600 700 0 5 10 15 20 LH or FSH ( mIU /mL) Total T (ng/dL) Hour After In - Clinic 24 - hr Assessment Start Week 16 24 - hr Assessment Androxal Subject ZA - 305 - 53 - 026 TT LH FSH Baseline Assessments Morning T

  17. Slide 17: Exogenous T Disrupts the HPT Axis

    Slide 17: Exogenous T Disrupts the HPT Axis

    Study ZA - 305 Exogenous T Disrupts the HPT Axis 0 1 2 3 4 5 6 7 8 9 0 100 200 300 400 500 600 700 800 900 1000 0 5 10 15 20 LH or FSH ( mIU /mL) Total T (ng/dL) Hour After In - Clinic 24 - hr Assessment Start Week 16 24 - hr Assessment Androgel Subject ZA - 305 - 52 - 008 TT LH FSH Baseline Assessm

  18. Slide 18: Impact on LH and FSH Consistent in all Comparator Studies

    Slide 18: Impact on LH and FSH Consistent in all Comparator Studies

    Impact on LH and FSH Consistent in all Repros Comparator Studies Study Androxal 12.5/25 mg Parallel/ Titrate Gel Comparator Per MFG. Duration Of Treatment Mean Change from Baseline LH ( std )/FSH( std ) p - value LH/FSH ZN - 018 ~ 10 per arm Parallel Androgel 1% 2 Weeks Androxal 12.5, 3.47 (2.80)/3.

  19. Slide 19: Androxal Averages % of Men Studied in Normal Range

    Slide 19: Androxal Averages % of Men Studied in Normal Range

    Androxal Averages > 75 % of Men Studied in Normal Range • 10 studies conducted with durations up to 1 year • Table determined as LOCF for morning T Study Subjects Receiving Androxal Study Duration % Morning T in Normal Range (LOCF) ZN - 018 22 2 Wks. 77.3 ZA - 003 97 3 Mo. 63.9 ZA - 203 57 3 Mo. 68.

  20. Slide 20: What Predicts Response?

    Slide 20: What Predicts Response?

    What Predicts Response? • Higher baseline testosterone levels (>216 ng/dL) predict better response • Obesity is associated with lower Tlevels • Duration of hypogonadism and prior testosterone therapy may influence outcomes – Should met with hypogonadism be treated earlier?

  21. Slide 21: Influence of Baseline Testosterone on Response

    Slide 21: Influence of Baseline Testosterone on Response

    Influence of Baseline Testosterone on Response ZA - 300, 6 month study

  22. Slide 22: Primary and Secondary Endpoints and Overall NDA Efficacy Findings

    Slide 22: Primary and Secondary Endpoints and Overall NDA Efficacy Findings

    Primary and Secondary Endpoints ZA - 304 & 305 Overall NDA Efficacy Findings & Clinical Implications Andrew McCullough, MD Professor of Surgery/Division of Urology Albany Medical College Director of Men’s Health/ Urological Institute of Northeastern NY Albany, NY

  23. Slide 23: Co-Primary Endpoint: Change in Sperm Concentration

    Slide 23: Co-Primary Endpoint: Change in Sperm Concentration

    ZA - 304 & 305 Co - Primary Efficacy Endpoint % Change from Baseline Sperm Concentration Androxal vs Androgel ZA-304 ZA-305 Androxal -1 6 Androgel -71 -33 -80 -70 -60 -50 -40 -30 -20 -10 0 10 Androgel Decreases Sperm Concentration p < 0.0001 p< 0.0005

  24. Slide 24: Co-Primary Endpoint: Normal T and Sperm Concentration

    Slide 24: Co-Primary Endpoint: Normal T and Sperm Concentration

    ZA - 304 & 305 Co - Primary Efficacy Endpoint % Normal T, 24 hr avg in range (300 - 1040ng/ dL ) and Sperm Concentration greater than 10 million Androxal vs Androgel ZA-304 ZA-305 Androxal 61 65.9 Androgel 16.3 33.3 0 10 20 30 40 50 60 70 % Normal Androxal normalizes T and maintains Sperm concentrat

  25. Slide 25: Secondary Endpoint: Changes in Mean LH & FSH

    Slide 25: Secondary Endpoint: Changes in Mean LH & FSH

    Secondary Endpoint: Changes in Mean LH & FSH LH 304 Baseline LH 304 EOS LH 305 Baseline LH 305 EOS FSH 304 Baseline FSH 304 EOS FSH 305 Baseline FSH 305 EOS Androxal 3.6 6.4 3.2 6.7 4.6 6.9 4.7 8.8 Androgel 3.8 0.7 3.4 1.4 5.8 1.5 3.8 2.1 Placebo 3 3 3.1 3.3 4.5 4.2 4.3 4 0 1 2 3 4 5 6 7 8 9 10 LH &

  26. Slide 26: Severely Oligospermic Subjects at End of Study

    Slide 26: Severely Oligospermic Subjects at End of Study

    Secondary Outcome: % of Subjects Severely Oligospermic (<10 million/ mL) at EOS ZA-304 ZA-305 Androxal 2.4 2.3 Androgel 44.2 23.8 Pbo 0 2.4 0 5 10 15 20 25 30 35 40 45 50 % Men with EOS Sperm Concentration <10 x 10 6 Androgel increases % of men with severe oligospermia p<0.0001 p < 0.004

  27. Slide 27: Change in Testicular Volume

    Slide 27: Change in Testicular Volume

    Secondary Outcome: Change in Testicular Volume by Orchidometry 304 BL Test. Vol. 304 EOS Test. Vol> 305 BL Test. Vol. 305 EOS Test. Vol> Androxal 20.7 21.27 19.1 19.4 Androgel 20.05 18.42 19.6 18.6 Pbo 20.35 21.36 19.3 19.8 16.5 17 17.5 18 18.5 19 19.5 20 20.5 21 21.5 22 cm 3 p< 0.014 p <0.03 Androg

  28. Slide 28: Impact on Spermatogenesis and Leydig Cell Synthesis of T

    Slide 28: Impact on Spermatogenesis and Leydig Cell Synthesis of T

    Impact on Spermatogenesis and Leydig Cell Synthesis of T Consistent with FSH and LH Findings Baseline T EOS T Off Drug T Baseline Sperm EOS Sperm 304 Androxal 203 435 377 98 102 305 Androxal 213 416 371 79 69 304 Androgel 209 339 176 79 40 305 Androgel 230 373 183 75 39 304 Pbo 200 231 229 95 69 305

  29. Slide 29: Are the Testosterone Findings for Topical T's Unusual?

    Slide 29: Are the Testosterone Findings for Topical T's Unusual?

    Are the Testosterone Findings for Topical T’s Unusual? • 304 and 305 report lower response than expected for Androgel 1.62% – Both studies followed manufacturer’s instructions – To facilitate “double dummy” design Androgel “Travel Packets” were used • Previous Repros Comparator Studies Yielded Simil

  30. Slide 30: Androxal Efficacy Summary

    Slide 30: Androxal Efficacy Summary

    Androxal Efficacy Summary • Treats well defined hypogonadal population • Androxal mechanism of action addresses secondary hypogonadism in men with BMI>25 – Enhances the HPT axis (Increases in LH and FSH) – Preserves testicular function (Maintains testis volume and Sperm production) – Oral therapy wi

  31. Slide 31: Prevalence of Hypogonadism in Middle-aged and Older Men

    Slide 31: Prevalence of Hypogonadism in Middle-aged and Older Men

    Glenn R. Cunningham, MD Professor of Medicine Molecular and Cellular Biology Baylor College of Medicine St. Luke’s - Baylor Diabetes Program Houston, Texas Prevalence of Hypogonadism in Middle - aged and Older Men & Implications for Clinical Management

  32. Slide 32: Location of the EMAS centres

    Slide 32: Location of the EMAS centres

    Location of the EMAS centres. Lee D M et al. Int. J. Epidemiol. 2013;42:391-401 Published by Oxford University Press on behalf of the International Epidemiological Association ©The Author 2012; all rights reserved.

  33. Slide 33: Categorising Gonadal Status in EMAS

    Slide 33: Categorising Gonadal Status in EMAS

    Categorising Gonadal Status by Testosterone (T) and LH in the European Male Ageing Study (EMAS) : A General Population Observational Cohort Study Thresholds for abnormal: <Total T 10.5 nmol /L (300 ng/ dL ) and >LH 9.4 U/L (Tajar et al J Clin Endocrinol Metab 2010 95:1810) 0 20 40 60 80 LH (U/L) 0 1

  34. Slide 34: Secondary Hypogonadism at Baseline

    Slide 34: Secondary Hypogonadism at Baseline

    Secondary Hypogonadism at Baseline Age (years) BMI ≥ 25 - <30 kg/m2 BMI ≥ 30 kg/m2 Smoking (current) Alcohol (frequent) Morbidity ( ≥ 1) 0 5 10 15 *** *** * Poor morning erection Sexual thoughts Erectile dysfunction Low vigorous activity Unable to bend Slow walking speed 0 2 4 6 * * Adjusted Relativ

  35. Slide 35: Production and Regulation of Testosterone

    Slide 35: Production and Regulation of Testosterone

    Production and Regulation of Testosterone T = testosterone Only 2% is free testosterone; 98% is bound Free T 2% SHBG - bound T 40% - 50% Albumin - bound T 48% Adapted from Bagatell CJ, Bremner WJ. N Engl J Med. 1996;334:707 - 714. GnRH LH FSH Testosterone Testosterone Sperm Hypothalamus Pituitary Te

  36. Slide 36: Greater Effects of BMI on Reproductive Hormone Levels in EMAS

    Slide 36: Greater Effects of BMI on Reproductive Hormone Levels in EMAS

    Wu et al. JCEM 2008 Greater Effects of BMI ( cf to Age) on Reproductive Hormone Levels in EMAS - Indicating Secondary Hypogonadism in Obesity (n = 3210)

  37. Slide 37: ATP III Clinical Identification of the Metabolic Syndrome

    Slide 37: ATP III Clinical Identification of the Metabolic Syndrome

    ATP III Clinical Identification of the Metabolic Syndrome JAMA 285:2486 – 2497, 2001 Parameter Measurement Waist Circumference Male >102 cm (>40 in) Female >88 cm (>35 in) Triglycerides ≥150 mg/dL HDL cholesterol Male <40 mg/dL Female <50 mg/dL Blood pressure ≥130/≥85 mm Hg Fasting glucose ≥110 mg/d

  38. Slide 38: International Diabetes Federation Consensus Statement

    Slide 38: International Diabetes Federation Consensus Statement

    International Diabetes Federation Consensus Statement (2013) http://www.idf.org/metabolic - syndrome • Estimated that 20 - 25% of Worlds’ adult population have MetS • MetS increases risk of MI or CVA 3 - fold • MetS increases risk of death 2 - fold • MetS increases risk of T2DM 5 - fold

  39. Slide 39: Two Separate Tracks of Hypogonadism

    Slide 39: Two Separate Tracks of Hypogonadism

    Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Two Separate Tracks of Hypogonadism 1. Secondary hypogonadism associated with ob

  40. Slide 40: Hormone Changes Related to Weight Loss/Gain

    Slide 40: Hormone Changes Related to Weight Loss/Gain

    Hormone Changes (Rise/Fall) are Related to % Weight Loss/Gain (Data adjusted for age , centre, changes in smoking status, alcohol consumption co - morbidities & physical activity) n = 2395, *p<0.05, **p<0.01 % Weight loss Weight gain % 0 * ** * * * * * * ** ** ** ** * Camacho et al. European Journal

  41. Slide 41: Clinical Implications

    Slide 41: Clinical Implications

    Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Institute of Human Development Centre for Endocrinology & Diabetes Manchester Academic Health Sciences Centre Clinical Implications • Secondary hypogonadism is closely associated with obesit

  42. Slide 42: Male hypogonadism and its relationship with obesity and the metabolic syndrome

    Slide 42: Male hypogonadism and its relationship with obesity and the metabolic syndrome

    Male hypogonadism and its relationship with obesity and the metabolic syndrome Prof. Nelly Pitteloud Andrew Dwyer Lausanne, Switzerland

  43. Slide 43: Decrease in Total & Free Testosterone with Increasing BMI

    Slide 43: Decrease in Total & Free Testosterone with Increasing BMI

    Total T Non - SHBG bound T Free T BMI (kg/m 2 ) % of Value at BMI of 22 Zumoff et al, J Clin Endocrinol Metab 1990 Decrease in Total & Free Testosterone (T) with Increasing BMI

  44. Slide 44: Impact of Hypogonadism on Insulin Sensitivity

    Slide 44: Impact of Hypogonadism on Insulin Sensitivity

    Impact of Hypogonadism on Insulin Sensitivity Metabolic Syndrome 1. Waist circumference: >102 cm 2. ↑ triglycerides: >150 mg/dL 3. ↓ HDL (good) cholesterol: <40 mg/dL 4. ↑ blood pressure: >130/85 mm Hg 5. ↑ fasting glucose: >100 mg/dL *p<0.05 0 2 4 6 8 10 * T<280 * 0 2 4 6 8 10 0 2 4 6 8 10 T >280 n

  45. Slide 45: Impact of the Metabolic Syndrome

    Slide 45: Impact of the Metabolic Syndrome

    International Diabetes Federation Consensus Statement (2013) • Effects ~ 20 - 25% of adult world population • 5 - fold increase in risk for type 2 diabetes • 3 - fold increase in risk of MI / CVA • 2 - fold increase risk of death Impact of the Metabolic Syndrome

  46. Slide 46: Low T Levels Increase the Risk of Developing Type 2 Diabetes

    Slide 46: Low T Levels Increase the Risk of Developing Type 2 Diabetes

    Low T Levels Increase the Risk of Developing Type 2 Diabetes in Men - Rancho Bernardo Study - 1.0 5.0 10.0 Oh et al, Diabetes Care 2002 Odds Ratio (95% CI) 2.7 (1.1 - 6.6)* Total Testosterone Men (n=294)

  47. Slide 47: Induced Hypogonadism Results in Insulin Resistance

    Slide 47: Induced Hypogonadism Results in Insulin Resistance

    Induced Hypogonadism Results in Insulin Resistance Smith et al, J Clin Endocrinol Metab 2001 * p<0.05 Baseline post 3 Months Weight (Kg) 83 ± 14 83 ± 14 Fat Mass (Kg) 20.2 ± 9.4 21.9 ± 9.6* Lean Body Mass (Kg) 63.2 ± 6.8 61.5 ± 6.0* Glucose (mmol/L) 5.7 ± 1.8 5.9 ± 2.7 Fasting Insulin (mU/L) 11.8 (5

  48. Slide 48: Hypogonadism is Common in Patients with Type 2 Diabetes

    Slide 48: Hypogonadism is Common in Patients with Type 2 Diabetes

    Hypogonadism is Common in Patients with Type 2 Diabetes Dhindsa et al, J Clin Endocrinol Metab 2004

  49. Slide 49: Hypogonadism in Type 2 Diabetes

    Slide 49: Hypogonadism in Type 2 Diabetes

    Hypogonadism in Type 2 Diabetes Hypogonadal Eugonadal number of patients 34 69 BMI 35.7 ± 2 31.7 ± 1 Testosterone (ng/dL) 230 ± 16 406 ± 15* LH (mIU/ml) 3.1 ± 0.3 3.9 ± 0.2* FSH (mIU/ml) 4.2 ± 0.4 5.5 ± 0.4* HbA1c (%) 8.5 ± 0.3 8.4 ± 0.2 Dhindsa et al, J Clin Endocrinol Metab 2004 * p<0.05 Hypogonad

  50. Slide 50: Serum T Decreases in Response to Glucose Tolerance Test

    Slide 50: Serum T Decreases in Response to Glucose Tolerance Test

    Serum T Decreases in Response to a Standard Oral Glucose Tolerance Test Total T (ng/dL) 350 400 450 500 550 * * * * * * * * * * * * Time (min) 0 30 60 90 120 NGT (n= 42) IGT (n= 23) T2DM (n= 9 ) * P<0.0001 vs. t=0 Caronia et al, Clin Endocrinol 2013

  51. Slide 51: Obesity-Induced Hypogonadism is Reversible

    Slide 51: Obesity-Induced Hypogonadism is Reversible

    Woodard, et al. British J Surgery 2012 Obesity - Induced Hypogonadism is Reversible

  52. Slide 52: Weight loss reduces the number of men with hypogonadal T

    Slide 52: Weight loss reduces the number of men with hypogonadal T

    Weight loss reduces the number of men with hypogonadal T (<300 ng/dL) BL 12 mos % Hypogonadal T 0 5 10 15 20 25 BL 12 mos BL 12 mos 0 5 10 15 20 25 0 5 10 15 20 25 Lifestyle Modification (7% weight loss: - 8Kg) (n=293) Metformin (850mg BID) (n=305) Placebo (n=293) * P<0.05 vs BL ↓ 46% * Dwyer, et al

  53. Slide 53: Beneficial effect of lifestyle changes on men with hypogonadal T levels

    Slide 53: Beneficial effect of lifestyle changes on men with hypogonadal T levels

    Beneficial effect of lifestyle changes on men with hypogonadal T levels 0 100 200 300 400 500 600 700 Normal T (>300 ng/dL) n=234 BL 12mos Low T (<300 ng/dL) n=59 BL 12mos Testosterone (ng/dL) Dwyer, et al. (unpublished) ENDO 2012 * p<0.001

  54. Slide 54: Behavioral Change is Difficult to Maintain

    Slide 54: Behavioral Change is Difficult to Maintain

    But...Behavioral Change is Difficult to Maintain Placebo Metformin Lifestyle DPP Research Group, New Engl J Med 2002 - 8 - 6 - 4 - 2 0 0 1 2 3 4 Years from Randomization Weight Change (kg)

  55. Slide 55: Summary & Take-Away Points

    Slide 55: Summary & Take-Away Points

    There is sufficient data supporting a link between obesity, insulin resistance & 2˚ hypogonadism in men. The disruption of the reproductive axis caused by obesity is reversible. Obese men with type 2 diabetes are at particularly high risk for developing 2˚ hypogonadism. Summary & Take - Away Points

  56. Slide 56: Thank you

    Slide 56: Thank you

    Thank you

  57. Slide 57: Effects of Long-Term Testosterone Therapy in Obese Hypogonadal Men

    Slide 57: Effects of Long-Term Testosterone Therapy in Obese Hypogonadal Men

    Effects of Long - Term Testosterone Therapy in Obese Hypogonadal Men Analyst’s Day at The Waldorf Astoria, New York, New York, October 31, 2014 Prof . h.c . Dr. Farid Saad, Global Medical Affairs Andrology, Bayer Pharma AG , Berlin, Germany, Gulf Medical University, Research Department, Ajman, Unite

  58. Slide 58: Obesity in America

    Slide 58: Obesity in America

    The Reaistet 9) | Obesity in America of adults with BMI* 230, 2011 - Mao. muse Economist con ore . —_ =i wo foes nana aney Ss The last course be m- phe What will it take to make the world less round? Os a N AWA >

  59. Slide 59: Abdominal Obesity as Therapeutic Target for Coronary Heart Disease Risk

    Slide 59: Abdominal Obesity as Therapeutic Target for Coronary Heart Disease Risk

    Després J - P et al. Brit Med J 322: 716 - 720 (2001) Contribution of Abdominal Obesity as Therapeutic Target for Better Management of Risk of Coronary Heart Disease Risk factors Coronary heart disease Abdominal obesity Treating the complications? Management of risk of coronary heart disease Treatin

  60. Slide 60: Waist Circumference Is a Cardio-Metabolic Risk Factor

    Slide 60: Waist Circumference Is a Cardio-Metabolic Risk Factor

    Waist Circumference Is a Well - Established Cardio - Metabolic Risk Factor and a Component of All Current Definitions of the Metabolic Syndrome

  61. Slide 61: What Are the Options for Treating Obesity?

    Slide 61: What Are the Options for Treating Obesity?

    What Are the Options for Treating Obesity ? 1. Lifestyle Interventions largely unsuccessful , typically resulting in U - shaped curve 2. Drugs largely unsuccessful , typically resulting in U - shaped curve ; targeting appetite control ; several drugs withdrawn from the market due to side effects 3.

  62. Slide 62: Approximately 50% of Obese Men Are Hypogonadal

    Slide 62: Approximately 50% of Obese Men Are Hypogonadal

    Approximately 50% of Obese Men Are Hypogonadal

  63. Slide 63: Observational Registry Studies from Germany

    Slide 63: Observational Registry Studies from Germany

    Observational Registry Studies from Germany

  64. Slide 64: Hypogonadal Men with Different Grades of Obesity from Registry Studies

    Slide 64: Hypogonadal Men with Different Grades of Obesity from Registry Studies

    362 Hypogonadal Men with Different Grades of Obesity from Two Ongoing Registry Studies

  65. Slide 65: Waist Circumference in 362 Hypogonadal Men

    Slide 65: Waist Circumference in 362 Hypogonadal Men

    95 100 105 110 115 120 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III * * * * 185 161 142 126 85 185 172 * * 131 122 104 90 64 131 125 46 43 37 34 24 46 46 * * * * * * * * * * * * # # # # # # # # # # # p=0.0132 p=0.0004 p=0.0021 p=NS - 9.24 cm - 12.29 cm - 12.44 cm * p

  66. Slide 66: Weight in 362 Hypogonadal Men

    Slide 66: Weight in 362 Hypogonadal Men

    85 90 95 100 105 110 115 120 125 130 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III Weight (kg ) in 362 Hypogonadal Men with Different Grades of Obesity Treated with Injections of Testosterone Undecanoate for up to 6 Years * * * * 185 159 141 126 84 177 169 Gr. I n = *

  67. Slide 67: Weight in 18 Individual Men with Obesity Grade III

    Slide 67: Weight in 18 Individual Men with Obesity Grade III

    92 97 102 107 112 117 122 127 132 137 142 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90 93 Weight (kg) in 18 Individual Men with Obesity Grade III Time ( months )

  68. Slide 68: Weight Loss (%)

    Slide 68: Weight Loss (%)

    -25 -20 -15 -10 -5 0 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III * p<0.0001 vs baseline for all groups * * * * * * - 12.28% - 17.66% - 20.83% Weight Loss (%) 185 159 141 126 84 177 169 Gr. I n = 131 121 104 90 64 124 125 Gr. II n= 46 43 37 34 24 44 46 Gr. III n=

  69. Slide 69: Total Cholesterol:HDL Ratio

    Slide 69: Total Cholesterol:HDL Ratio

    2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III Total Cholesterol : HDL Ratio 185 161 142 125 82 185 171 131 122 104 89 60 131 125 46 43 37 35 24 46 46 - 2.92 - 2.83 - 2.61 * * * * * * * * p<0.0001 vs baseline # p<0.0001 vs previous year

  70. Slide 70: Systolic Blood Pressure

    Slide 70: Systolic Blood Pressure

    120 125 130 135 140 145 150 155 160 165 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III Systolic Blood Pressure (mmHg) * * * * 184 156 136 120 79 184 172 * * 131 118 100 86 60 131 125 46 42 36 34 24 46 44 * * * * * * * # # # # NS - 16.19 - 23.63 - 22.67 mmHg * p<0.0001

  71. Slide 71: Diastolic Blood Pressure

    Slide 71: Diastolic Blood Pressure

    70 75 80 85 90 95 100 Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Grade I Grade II Grade III Diastolic Blood Pressure (mmHg) * * * * * * * * * * * * * # # # # NS - 7.72 - 15.14 - 17.82 mmHg * p<0.0001 vs baseline # p<0.0001 vs previous year p=0.0272 NS NS p =0.046 * NS * NS * NS * NS * NS NS

  72. Slide 72: Hypogonadal Men with Type 2 Diabetes Mellitus from a Registry Study

    Slide 72: Hypogonadal Men with Type 2 Diabetes Mellitus from a Registry Study

    120 Hypogonadal Men with Type 2 Diabetes Mellitus (T2DM) from an Ongoing Registry Study

  73. Slide 73: Distribution of BMI Categories in Hypogonadal Men with T2DM

    Slide 73: Distribution of BMI Categories in Hypogonadal Men with T2DM

    Distribution of BMI Categories in 120 Hypogonadal Men with T2DM BMI category n Proportion (%) Normal weight (≤ 24.9) 4 3 Overweight (25 - 29.9) 9 8 Obese (30 - 40) 107 89

  74. Slide 74: Body Weight

    Slide 74: Body Weight

    88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 * p<0.0001 vs baseline # p<0.0001 vs previous year * * # - 21.36 kg * p = NS 120 N= 120 120 117 100 85 83 75 68 64 63 60 29 52 46 * #

  75. Slide 75: Weight Change from Baseline

    Slide 75: Weight Change from Baseline

    -20 -15 -10 -5 0 5 10 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 obese overweight normal weight Weight Change (% from Baseline) * p<0.0001 vs baseline + 2.82% * 120 N= 120 120 117 100 85 83 75 68 64 63 60 29 52 46 - 13.64% - 18.24%

  76. Slide 76: Waist Circumference

    Slide 76: Waist Circumference

    98 99 100 101 102 103 104 105 106 107 108 109 110 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 * p<0.0001 vs baseline # p<0.0001 vs previous year Waist Circumference (cm) * * # * - 11.34 cm p = 0.0043 120 N= 120 120 117 100 85 83 75 68 64 63 60 29 52 46 * # * #

  77. Slide 77: Fasting Glucose

    Slide 77: Fasting Glucose

    95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 * p<0.0001 vs baseline * * - 22.57 mg/dl Fasting Glucose (mg/dl) p = 0.0002 * * p = NS 120 N= 120 119 117 100 85 83 75 68 64 63 60 29 52 4

  78. Slide 78: HbA1c (%)

    Slide 78: HbA1c (%)

    5.7 5.9 6.1 6.3 6.5 6.7 6.9 7.1 7.3 7.5 7.7 7.9 8.1 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 - 2.28% * p<0.0001 vs baseline # p<0.0001 vs previous year * * # * * * * * HbA 1c (%) 120 N= 79 73 69 67 53 56 49 46 44 44 40 18 37 32 # # # p = 0.0079 p = 0.0001

  79. Slide 79: Patients Reaching HbA1c Target of 7.0% or Less

    Slide 79: Patients Reaching HbA1c Target of 7.0% or Less

    Patients Reaching HbA 1c Target of ≤ 7.0% at various Time Points 0% 100% 93% 7% 11% 89% 0 10 20 30 40 50 60 70 80 90 100 no (n=107) yes (n=13) no (n=4) yes (n=56) no (n=0) yes (n=29) baseline end point (84 months) T22 (66 months)

  80. Slide 80: HbA1c in Individual Hypogonadal Men with Obesity Grade III and T2DM

    Slide 80: HbA1c in Individual Hypogonadal Men with Obesity Grade III and T2DM

    5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90 93 HbA 1c (%) in Individual Hypogonadal Men with Obesity Grade III and Type 2 Diabetes mellitus Haider A, Saad F et al ., unpublished

  81. Slide 81: Observational Data Confirmed by A Controlled Study

    Slide 81: Observational Data Confirmed by A Controlled Study

    Observational Data Confirmed by A Controlled Study

  82. Slide 82: Effects of Treatment with TU Injections on Waist Circumference

    Slide 82: Effects of Treatment with TU Injections on Waist Circumference

    Effects of 5 years Treatment with TU Injections on Δ Waist Circumference (cm) in 40 Hypogonadal Men (T<11 nmol/L) with Metabolic Syndrome (IDF) 0 -3.8 -5.5 -6.5 -7.8 -9.6 0 0.3 1 0.9 1.8 3.1 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 baseline 12 months 24 months 36 months 48 months 60 months Change in

  83. Slide 83: Change in Body Weight

    Slide 83: Change in Body Weight

    Δ Body Weight (kg) 0 -5.7 -9.6 -11.1 -13.7 -15.4 0 -0.2 0.4 0.4 0.6 0.9 -20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 baseline 12 months 24 months 36 months 48 months 60 months Change in Weight (kg) Testosterone (n=20) Control (n=20) ** *** *** *** *** ** p=0.001; *** p=0.0001 between testosterone and con

  84. Slide 84: Effects of Long-Acting TU on HbA1c

    Slide 84: Effects of Long-Acting TU on HbA1c

    Effects of 5 years Treatment with Long - Acting TU on Δ HbA 1c (%) in 40 Hypogonadal Men (T<11 nmol/L) with Metabolic Syndrome (IDF) 0 -0.9 -1.1 -1.4 -1.3 -1.6 0 0.3 0.4 0.4 0.5 0.3 -2 -1.8 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1 baseline 12 months 24 months 36 months 48 months 60

  85. Slide 85: Influence of Trial Duration on BMI after Injectable TU Therapy

    Slide 85: Influence of Trial Duration on BMI after Injectable TU Therapy

    S= - 0.07[ - 0.08; - 0.05];p<0.0001 I=0.49[0.18;0.80];p=0.002 Trial duration (months) Difference in means 0 4,1 10,9 17,8 24,6 31,5 38,3 45,2 52,0 58,9 65,7 3,00 2,10 1,20 0,30 - 0,60 - 1,50 - 2,40 - 3,30 - 4,20 - 5,10 - 6,00 Corona G et al. Expert Opin Pharmacother 15(13): 1903 - 1926 (2014) Regres

  86. Slide 86: Summary

    Slide 86: Summary

    Summary  Obesity is a risk factor for hypogonadism and vice versa.  50% of obese men are hypogonadal.  In three independent registry studies of unselected hypogonadal men, 50 - 70% of men were obese at baseline.  Testosterone therapy induces meaningful and sustained weight loss.  In men with ty

  87. Slide 87: Androxal Safety Review October 2014

    Slide 87: Androxal Safety Review October 2014

    Androxal Safety Review 31 October 2014 ▪ Discontinuation due to Adverse Events (DCAEs) ▪ Treatment Emergent Adverse Events ( TEAEs) ▪ Thrombotic events ▪ Prostate Specific Antigen (PSA) ▪ Other Safety Issues Related to Testosterone Therapy

  88. Slide 88: Discontinuations Due to Adverse Events: Short-term studies

    Slide 88: Discontinuations Due to Adverse Events: Short-term studies

    DISCONTINUATIONS DUE TO ADVERSE EVENTS Short - term studies Study 301 302 304 305 N 12.5 mg – 91 25 mg – 21 PBO - 37 12.5 mg - 112 25 mg - 22 PBO - 47 12.5 mg – 24 25 mg – 17 Androgel – 43 Placebo - 45 12.5 mg - 19 25 mg - 25 Androgel - 42 Placebo - 41 TOTAL DCAE 12.5 - 1 PBO - 1 12.5 - 3 AndroGel -

  89. Slide 89: Discontinuations Due to Adverse Events: ZA-300 6-month study

    Slide 89: Discontinuations Due to Adverse Events: ZA-300 6-month study

    DISCONTINUATIONS DUE TO ADVERSE EVENTS ZA - 300 – 6 month study 12.5 mg 25 mg N 207 283 TOTAL DCAEs TOTAL Events 15 (7.2%) 19 8 (2.8%) 13 Event Pollakiuria 1 Pulmonary Embolism 1 Deep Vein Thrombosis 1 Muscle Spasms 1 Paraesthesia 1 Aggression 1 Constipation 1 Vitreous Floaters 1 Prostatitis 1 Flank

  90. Slide 90: Discontinuations Due to Adverse Events: ZA-303 1-year study

    Slide 90: Discontinuations Due to Adverse Events: ZA-303 1-year study

    DISCONTINUATIONS DUE TO ADVERSE EVENTS ZA - 303 – 1 year study 12.5 mg 25 mg Placebo N 122 91 104 TOTAL DCAEs TOTAL Events 11 (9.02%) 18 7 (7.69%) 9 2 (1.9%) 3 EVENT Polycythemia 1 Corneal opacity 1 Eye pain 1 1 Chest pain 1 Exercise tolerance decreased 1 Fatigue 1 Irritability 1 Ligament rupture 1

  91. Slide 91: Treatment Emergent Adverse Events: Short-term studies 301 & 302

    Slide 91: Treatment Emergent Adverse Events: Short-term studies 301 & 302

    TREATMENT EMERGENT ADVERSE EVENTS ZA - 301 & ZA - 302 - Short - term studies Study 301 Study 302 Preferred Term 12.5 mg (%) 25 mg (%) PBO (%) 12.5 mg (%) 25 mg (%) PBO (%) N 91 21 37 112 22 47 Any Event 28 24 24 35 36 34 Diarrhea 2 0 3 2 0 0 Dyspepsia 2 0 0 1 0 2 Nausea 0 0 5 4 5 6 Hot flush 1 0 0 2

  92. Slide 92: Treatment Emergent Adverse Events: ZA-304 & ZA-305

    Slide 92: Treatment Emergent Adverse Events: ZA-304 & ZA-305

    ZA - 304 ZA - 305 Androxal Pooled Androgel Placebo Androxal Pooled Androgel Placebo N=41 N=43 N=45 N=44 N=42 N=41 (%) (%) (%) (%) (%) (%) Any event 48.8 41.9 42.2 45.5 47.6 46.3 Preferred Term Cataract 0 4 .7 0 0 0 0 Abnormal Weight Gain 0 0 0 2.3 4.8 2.4 Arthralgia 2.4 4.7 0 0 0 2.4 Cough 0 0 0 0 4

  93. Slide 93: Treatment Emergent Adverse Events: Long-term studies

    Slide 93: Treatment Emergent Adverse Events: Long-term studies

    TREATMENT EMERGENT ADVERSE EVENTS Studies 300 and 303 - Long - term studies Study 300 (>2% in either dose) Study 303 (>2% in either Androxal group ) Preferred Term 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 207 283 120 91 103 Any Event 59.9 58.7 63.3 62.6 51.5 CONSTIPATION 1.9 2.5 0 0 0 D

  94. Slide 94: Treatment Emergent Adverse Events (continued)

    Slide 94: Treatment Emergent Adverse Events (continued)

    TREATMENT EMERGENT ADVERSE EVENTS Studies 300 and 303 (continued) Study 300 (>2% in either dose) Study 303 (>2% in either Androxal group ) Preferred Term 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 207 283 120 91 103 Any Event 59.9 58.7 63.3 62.6 51.5 ARTHRALGIA 1.9 1.8 5.8 3.3 1.9 BACK PA

  95. Slide 95: ZA-300-02-029: DVT & PE

    Slide 95: ZA-300-02-029: DVT & PE

    ZA - 300 - 02 - 029: DVT & PE • 49 y/o with risk factor for thrombus: African American , 6’5” tall , obesity (BMI 39.4), hypertension , FHx of clotting disorder , standing at work (possible travel) • Leg pain, ankle swelling, shortness of breath • Deep vein thrombosis of leg and bilateral pulmonary

  96. Slide 96: ZA-304-22-028: Ischemic stroke (fatal)

    Slide 96: ZA-304-22-028: Ischemic stroke (fatal)

    ZA - 304 - 22 - 028: Ischemic stroke (fatal ) • 59 year old Caucasian with risk factors for stroke: type 2 diabetes , obesity (BMI 41.8), gastric bypass, atrial fibrillation (UNTREATED) , sleep apnea , hyperlipidemia • Middle cerebral artery thrombotic stroke 36 days after starting Androxal 12.5 mg/

  97. Slide 97: FDA Broadens Warning About Venous Blood Clots

    Slide 97: FDA Broadens Warning About Venous Blood Clots

    FDA Broadens Warning About Venous Blood Clots (19 June 2014) “The risk of venous blood clots is already included in the labeling of testosterone products as a possible consequence of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment

  98. Slide 98: PSA

    Slide 98: PSA

    PSA • PSA elevation is NOT an Adverse Drug Reaction • PSA elevation is an expected result of testosterone increase • PSA is not a cancer marker but a normal enzyme • Elevated PSA included in package insert for Axiron • Incidence and magnitude noted in Androxal studies is not alarming and has been re

  99. Slide 99: Other Safety Issues Related to Testosterone Therapy

    Slide 99: Other Safety Issues Related to Testosterone Therapy

    OTHER SAFETY ISSUES RELATED TO TESTOSTERONE THERAPY • Cataracts – No evidence of cataract formation or progression in Androxal groups • Osteoporosis – Data suggests that Androxal subjects are no worse than placebo subjects – ZA - 303 found no deleterious bone effects in subjects with over 1 year of

  100. Slide 100: Conclusions

    Slide 100: Conclusions

    CONCLUSIONS • Androxal is well tolerated • Findings are consistent with known pharmacology • Thrombotic events (with or without Hct increase) are an established risk (similar to topical testosterone) • No unexpected safety issues

  101. Slide 101: Preview of Commercial Findings

    Slide 101: Preview of Commercial Findings

    Preview of Commercial Findings Key Commercial Conclusions ▪ Payers and providers recognize room for improvement with current treatment options and are becoming more aware of the downsides of TRTs. ▪ Additional education will be important to inform physicians and payers as to the issues associated wi

  102. Slide 102: Q & A

    Slide 102: Q & A

    Q & A

  103. Slide 103: Summary of Provider and Payer Perspectives Regarding Androxal

    Slide 103: Summary of Provider and Payer Perspectives Regarding Androxal

    Summary of Provider and Payer Perspectives Regarding Androxal October 31, 2014

  104. Slide 104: Research Background Key Topics

    Slide 104: Research Background Key Topics

    Research Background Key Topics Quintiles conducted interviews with 30 physicians and 20 payers covering these key topics. • Role in managing patient treatment for primary and secondary hypogonadism • Understanding and perceptions of existing therapies and developments • Satisfaction with existing th

  105. Slide 105: Providers

    Slide 105: Providers

    ) QUINTILES’ Providers

  106. Slide 106: Secondary Hypogonadism TRT Usage

    Slide 106: Secondary Hypogonadism TRT Usage

    Secondary Hypogonadism Testosterone Replacement Therapy (TRT) Usage On average, three quarters of secondary hypogonadism patients are on TRT regardless of physician specialty, with Androgel as the most often mentioned choice. Total Physician Respondents (n=30) Uro (n=10), Endo (n=10), PCP (n=10) Fre

  107. Slide 107: Current Satisfaction with Available Treatments

    Slide 107: Current Satisfaction with Available Treatments

    Secondary Hypogonadism Current Satisfaction with Available Treatments Physicians are less satisfied with current treatments than the think their patients are. Physician Satisfaction Perceived Patient Satisfaction Count of Physicians Total Physician Respondents (n=30) Uro (n=10), Endo (n=10), PCP (n=

  108. Slide 108: Secondary Hypogonadism Unmet Needs

    Slide 108: Secondary Hypogonadism Unmet Needs

    Secondary Hypogonadism Unmet Needs The top unmet needs were a better route of administration and testicular function/infertility. Comments About Unmet Needs ▪ A third of providers voiced minor - moderate concern over CV risks. ▪ Physicians do not view transference as a major problem. ▪ Although TRT

  109. Slide 109: Androxal Review: Advantages and Disadvantages

    Slide 109: Androxal Review: Advantages and Disadvantages

    Androxal Review Advantages and Disadvantages All physicians interviewed expressed excitement and interest in using Androxal, rating it an average 9.1 out of 10 (10=very attractive) in terms of attractiveness to their practice. Unmet Needs Product X Addresses PCP Endocrinologist Urologist Total Physi

  110. Slide 110: Androxal Review: Expected Physician Usage

    Slide 110: Androxal Review: Expected Physician Usage

    Androxal Review Expected Physician Usage All providers in the study would consider using Androxal as a first line treatment and would place nearly 60 of their next 100 secondary hypogonadal patients on Androxal. First Line Treatment Mentions Total Physician Respondents (n=30) Uro (n=10), Endo (n=10)

  111. Slide 111: Payers

    Slide 111: Payers

    ) QUINTILES’

  112. Slide 112: Secondary Hypogonadism Current Budget Impact

    Slide 112: Secondary Hypogonadism Current Budget Impact

    Secondary Hypogonadism Current Budget Impact In terms of pharmacy budget impact, the products for secondary hypogonadism are generally outside the top 25 as a category, keeping them off the radar for most plans. Most mentioned that they were mostly concerned with all the DTC advertising for products

  113. Slide 113: Secondary Hypogonadism Current Satisfaction

    Slide 113: Secondary Hypogonadism Current Satisfaction

    Secondary Hypogonadism Current Satisfaction Satisfaction with existing therapies was high, with an average rating of 3.8 out of 5 . Most indicated that the products work but have risk of transference and other safety issues. 113

  114. Slide 114: Secondary Hypogonadism Unmet Needs

    Slide 114: Secondary Hypogonadism Unmet Needs

    Secondary Hypogonadism Unmet Needs The risk of transference, the potential cardiovascular risks and infertility effects associated with testosterone replacement therapies (TRTs) were the key issues. 114

  115. Slide 115: Current Product Formulary Positions – Commercial

    Slide 115: Current Product Formulary Positions – Commercial

    Secondary Hypogonadism Current Product Formulary Positions – Commercial Androgel products and Axiron enjoyed the most preferred access, largely due to contracts. Percent of Total Lives Across Commercial Formulary Placement for Current Products 115

  116. Slide 116: Androxal Review: Positives and Negatives

    Slide 116: Androxal Review: Positives and Negatives

    Androxal Review Positives and Negatives Androxal was seen as an elegant addition for the treatment of secondary hypogonadism. Most of the concerns were merely questions that need to be addressed. Total Mentions (multiple mentions allowed) Positive Aspects of Product X (n=20) Total Mentions (multiple

  117. Slide 117: Androxal Review: Payer Pricing Expectations

    Slide 117: Androxal Review: Payer Pricing Expectations

    Unaided, a majority believed that Androxal would be priced similar to branded TRTs and, at that price, would be covered. Androxal Review Payer Pricing Expectations Responses Payer Expectations of Androxal Price 117

  118. Slide 118: Conclusions

    Slide 118: Conclusions

    Conclusions Key Commercial Conclusions ▪ Payers and providers recognize room for improvement with current treatment options and are becoming more aware of the downsides of TRTs. ▪ Additional education will be important to inform physicians and payers as to the issues associated with testosterone rep

  119. Slide 119: Thank you

    Slide 119: Thank you

    Thank you For further information and review of this presentation, please visit www.reprosrx.com

Source: SEC EDGAR · 8-K filed Oct 31, 2014

More decks from Repros Therapeutics